Aspiriant LLC’s Becton Dickinson BDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,330
Closed -$305K 310
2025
Q1
$305K Buy
1,330
+209
+19% +$48.5K 0.01% 235
2024
Q4
$254K Sell
1,121
-50
-4% -$11.5K 0.01% 254
2024
Q3
$282K Buy
1,171
+91
+8% +$21.3K 0.01% 241
2024
Q2
$252K Sell
1,080
-78
-7% -$18.4K 0.01% 252
2024
Q1
$287K Sell
1,158
-26
-2% -$6.22K 0.01% 250
2023
Q4
$289K Sell
1,184
-15
-1% -$3.7K 0.01% 249
2023
Q3
$310K Buy
1,199
+11
+0.9% +$2.97K 0.02% 216
2023
Q2
$314K Hold
1,188
0.02% 215
2023
Q1
$294K Hold
1,188
0.02% 221
2022
Q4
$302K Buy
1,188
+105
+10% +$24.8K 0.02% 213
2022
Q3
$241K Sell
1,083
-13
-1% -$3.23K 0.01% 230
2022
Q2
$271K Sell
1,096
-64
-6% -$16.3K 0.01% 224
2022
Q1
$302K Sell
1,160
-2
-0.2% -$515 0.02% 224
2021
Q4
$286K Buy
1,162
+151
+15% +$36.2K 0.02% 231
2021
Q3
$242K Buy
1,011
+1
+0.1% +$245 0.01% 213
2021
Q2
$238K Buy
1,010
+11
+1% +$2.64K 0.01% 216
2021
Q1
$236K Sell
999
-9
-0.9% -$2.2K 0.02% 189
2020
Q4
$247K Sell
1,008
-2
-0.2% -$466 0.02% 187
2020
Q3
$230K Buy
1,010
+1
+0.1% +$246 0.02% 200
2020
Q2
$235K Sell
1,009
-135
-12% -$32.5K 0.02% 169
2020
Q1
$256K Sell
1,144
-127
-10% -$31.4K 0.03% 166
2019
Q4
$337K Hold
1,271
0.03% 164
2019
Q3
$314K Sell
1,271
-33
-3% -$8.15K 0.03% 173
2019
Q2
$320K Sell
1,304
-146
-10% -$33.9K 0.03% 174
2019
Q1
$352K Sell
1,450
-127
-8% -$30K 0.03% 169
2018
Q4
$345K Sell
1,577
-123
-7% -$28.5K 0.03% 173
2018
Q3
$432K Buy
1,700
+155
+10% +$38.2K 0.04% 164
2018
Q2
$361K Buy
1,545
+50
+3% +$11.1K 0.03% 185
2018
Q1
$316K Buy
+1,495
New +$327K 0.03% 189
2017
Q4
Sell
-1,534
Closed -$293K 92
2017
Q3
$293K Buy
1,534
+27
+2% +$5.24K 0.02% 167
2017
Q2
$287K Sell
1,507
-480
-24% -$87.7K 0.03% 174
2017
Q1
$356K Buy
1,987
+377
+23% +$65.7K 0.03% 165
2016
Q4
$260K Sell
1,610
-505
-24% -$83.8K 0.02% 168
2016
Q3
$371K Buy
+2,115
New +$362K 0.04% 153

Other funds holding BDX

Aspiriant LLC's BDX Position: Q2 2025 in Review

Aspiriant LLC sold out of Becton Dickinson (BDX) in Q2 2025, closing a stake of 1,330 shares — an estimated $305K sold.

Aspiriant LLC first reported a position in BDX in Q3 2016 and held it in 34 quarters. The position peaked at $432K in Q3 2018. 1,516 funds tracked by Wall St. Rank hold BDX as of Q2 2025.

  • Aspiriant LLC reported no remaining Becton Dickinson position as of Q2 2025 after selling out during the quarter.
  • Aspiriant LLC sold 1,330 Becton Dickinson shares in Q2 2025, an estimated $305K.
  • Aspiriant LLC first reported a position in Becton Dickinson in Q3 2016 and held it in 34 quarters.
  • Aspiriant LLC's Becton Dickinson position peaked at $432K in Q3 2018.
  • 1,516 funds tracked by Wall St. Rank held Becton Dickinson as of Q2 2025.

Based on Aspiriant LLC's 13F filing for Q2 2025, filed 29 Jul 2025.